Dr. Denise Feick

Forschungsgebiet

Physiologie-basierte Pharmakokinetik (PBPK) Modellierung von komplexen Arzneimittel-Gen-Interaktionen

Lebenslauf

Seit 01/2023: Wissenschaftliche Mitarbeiterin in der Klinischen Pharmazie, Universität des Saarlandes, Saarbrücken

12/2017 – 12/2022: Promotion, Klinische Pharmazie, Universität des Saarlandes, Saarbrücken

11/2017: Approbation als Apothekerin

11/2016 – 04/2017: Diplom, Klinischen Pharmazie, Universität des Saarlandes, Saarbrücken

10/2012 – 09/2016: Studium der Pharmazie, Universität des Saarlandes, Saarbrücken

06/2012: Allgemeine Hochschulreife, Warndtgymnasium, Völklingen

Publikationen

Manuskripte

Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug–drug–gene interaction network. CPT Pharmacometrics Syst Pharmacol 2023;00:1-14

Türk D, Scherer N, Selzer D, Dings C, Hanke N, Dallmann R, Schwab M, Timmins P, Nock V, Lehr T. Significant impact of time-of-day variation on metformin pharmacokinetics. Diabetologia 2023.

Loer HLH, Feick D, Rüdesheim S, Selzer D, Schwab M, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Lehr T. Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions. CPT Pharmacometrics Syst Pharmacol 2023;00:1-15.

Türk D, Müller F, Fromm MF, Selzer D, Dallmann R, Lehr T. Renal transporter-mediated drug-biomarker interactions of the endogenous substrates creatinine and N1-methylnicotinamide: a PBPK modeling approach. Clin Pharmacol Ther 2022;112(3):687-698.

Loer HLH, Türk D, Gómez-Mantilla JD, Selzer D, Lehr T. Physiologically based pharmakokinetic (PBPK) modeling of clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19 and CYP3A4 drug-drug-gene interaction predictions. Pharmaceutics 2022;14(5):915.

Türk D, Fuhr LM, Marok FZ, Rüdesheim S, Kühn A, Selzer D, Schwab M, Lehr T. Novel models for the prediction of drug-gene interactions. Expert Opin on Drug Metab Toxicol 2021;17(11):1293-1310.

Türk D, Hanke N, Lehr T. A physiologically-based pharmacokinetic model of trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 drug-drug-gene interaction predictions. Pharmaceutics 2020;12(11):1074.

Hanke N, Türk D, Selzer D, Wiebe S, Fernandez É, Stopfer P, Nock V, Lehr T. A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies. Pharmaceutics 2020;12(6):556.

Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, Stopfer P, Nock V, Lehr T. A comprehensive whole-body physiologically based pharmacokinetic drug-drug-gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. Clin Pharmacokinet 2020;59:1419-1431.

Türk D, Hanke N, Wolf S, Frechen S, Eissing T, Wendl T, Schwab M, Lehr T. Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug-drug-gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. Clin Pharmacokinet 2019;58(12):1595-1607.

Poster

Türk D, Müller F, Poster Fromm MF, Selzer D, Dallmann R, and Lehr T. PBPK models for OCT2 and MATE interaction predictions: a drug-biomarker interaction network of creatinine, N1-methylnicotinamide, trimethoprim, pyrimethamine and cimetidine. American Conference on Pharmacometrics (ACoP)13. 2022. Aurora, United States.

Loer HLH, Türk D, Selzer D, Lehr T. Dose Adaptations for Drug–Gene and Drug–Drug Interactions Involving Clopidogrel – A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach. 30th Population Approach Group Europe (PAGE) meeting, 2022, Ljubljana, Slovenia.

Türk D, Hanke N, Lehr T. Physiologically-based pharmacokinetic models to predict CYP2C8 drug-drug interactions: a modeling network of trimethoprim, repaglinide, pioglitazone and rifampicin. International PhD Student & Postdoc Meeting of the German Pharmaceutical Society (DPhG) 2021, Virtual Meeting, Germany.

Türk D, Hanke N, Lehr T. Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim. 28th Population Approach Group Europe (PAGE) meeting, 2019, Stockholm, Sweden.

Türk D, Hanke N, Lehr T. Physiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone. 27th Population Approach Group Europe (PAGE) meeting, 2018, Montreux, Switzerland.

Türk D, Hanke N, Lehr T. Physiologically-based pharmacokinetic (PBPK) modeling of the CYP2C8 substrate pioglitazone. 26th Population Approach Group Europe (PAGE) meeting, 2017, Budapest, Hungary.